Sandeep Bansal, MD
Pulmonary Disease · du Bois, PANPI 1215105267
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,059,063 of the $1,426,282 with a category attached, or 74.3%. 59 manufacturers reported payments, led by GSK at 31.1% of the total. 2025 is the largest year on record at $280,538, 3.0 times the $94,745 reported in 2019. Among pulmonary disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,766 payments — averaging $807.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$443K
- Regeneron Healthcare Solutions, Inc.$269K
- Sanofi$266K
- AstraZeneca$103K
- Boehringer Ingelheim$78K
- Takeda Pharmaceuticals U.S.A., Inc.$45K
- plus $222K from 53 others
Across 847 payments — averaging $8794.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$2.8M
- AstraZeneca$2.1M
- Sanofi US Services Inc.$856K
- GSK$664K
- Boehringer Ingelheim$371K
- Johnson & Johnson$154K
- plus $557K from 14 others
What the payments were for
- Consulting fees$147,94610%
- Speaking & faculty fees$1,059,06374%
- Travel & lodging$181,70613%
- Food & beverage$37,1133%
- Education$4230%
- Entertainment$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$537,184
- NUCALA$225,419
- TRELEGY ELLIPTA$95,748
- TEZSPIRE$83,483
- OFEV$56,973
- Monarch Platform$50,469
- GLASSIA$42,834
- Ohtuvayre$42,730
- AREXVY$30,843
- AIRSUPRA$29,676
- Spin$28,266
- Yupelri$26,188
- MONARCH$22,655
- Accent Pacemaker$10,500
- GALAXY$9,167
- Photofrin$6,759
- ANORO$5,233
- XOLAIR$1,780
- Inspire Upper Airway Stimulation System$1,762
- ALIYA SYSTEM$400
How this compares
$1,426,282 in reported general payments places this provider in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 151 | $606,785 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 704 | $536,982 |
| GlassiaAlpha-1-Proteinase Inhibitor | 26 | $368,275 |
| OfevNintedanib Esylate | 29 | $357,258 |
| NucalaMepolizumab | 49 | $183,757 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $154,985 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 220 | $118,163 |
| TezspireTezepelumab-Ekko | 25 | $111,626 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 119 | $82,487 |
| Breo ElliptaFluticasone/Vilanterol | 170 | $71,922 |
| Spiriva RespimatTiotropium Bromide | 97 | $49,318 |
| Pirfenidone | 12 | $44,548 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 212 | $33,264 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 47 | $26,782 |
| Arnuity ElliptaFluticasone Furoate | 109 | $23,610 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $443,239 | $947,4671,285 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $78,089 | $433,357173 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $44,953 | $368,27526 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $102,576 | $197,804161 claims |
| Grifols USA, LLCProlastin C | $89 | $154,98511 claims |
| MerckAsmanex | $104 | $2,02817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in du Bois
- Alan KanouffAltoona$809K
- Gerard CrinerPhiladelphia$657K
- Kenneth LanderUpland$647K
- Richard FriedenheimAbington$627K
- Thomas MeyerWynnewood$615K
- Surya BhattBethlehem$579K
- Tariq CheemaPittsburgh$549K
- Stephen KovacsErie$520K
- Michael ZlupkoAltoona$468K
- Stephen BashedaPittsburgh$455K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.